Loading
Tookad is a light-activated drug for men with low-risk prostate cancer in one side of the prostate. It is infused and then switched on with laser fibres placed in the gland, destroying the cancer-bearing tissue as an alternative to watchful waiting.
Padeliporfin was authorised in the EU in November 2017 as monotherapy for previously untreated, unilateral, low-risk prostate adenocarcinoma (stage T1c or T2a, Gleason 6, PSA 10 ng/mL or below) in men with a life expectancy of at least 10 years, on the PCM301 phase 3 trial in which vascular-targeted photodynamic therapy roughly halved progression and the need for radical therapy compared with active surveillance, at the cost of transient urinary and erectile symptoms. It is the only focal drug-device therapy for prostate cancer with a marketing authorisation; an FDA advisory committee questioned its benefit over surveillance and it is not approved in the US. Trials in intermediate-risk disease and in upper urinary tract urothelial cancer are ongoing. Dysuria, haematuria and erectile dysfunction are the main adverse effects and patients must avoid light exposure for 48 hours.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Water-soluble bacteriochlorophyll derivative that stays in the circulation; activation by 753 nm laser light delivered through transperineal fibres generates oxygen radicals that occlude tumour vasculature and cause focal necrosis of the treated prostate lobe.
1.Padeliporfin slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2017 | Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Padeliporfin" OR ABSTRACT:"Padeliporfin" OR TITLE:"Tookad" OR ABSTRACT:"Tookad" OR TITLE:"WST11" OR ABSTRACT:"WST11" OR TITLE:"Padeliporfin di-potassium" OR ABSTRACT:"Padeliporfin di-potassium" OR TITLE:"Vascular-targeted photodynamic therapy VTP" OR ABSTRACT:"Vascular-targeted photodynamic therapy VTP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Padeliporfin, not a curated reading list.
Shares Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance, Focal and tissue-preserving treatment of prostate cancer, Active surveillance and observation, Active surveillance.
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
Shares Active surveillance and observation, Active surveillance.
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
Shares Active surveillance, Prostate cancer.
Shares Active surveillance and observation, Active surveillance.